A subfamília p21 RAS de pequenas GTPases, incluindo KRAS, HRAS e NRAS, participa de muitas redes de sinalização, incluindo proliferação celular, organização do citoesqueleto e apoptose, e é o alvo mais freqüente de mutações ativadoras em câncer. Mutações germinativas em KRAS e HRAS causam graves anormalidades desenvolvimentais levando às síndromes de Noonan, cárdio-facial-cutânea e Costello, porem mutações ativadoras germinativas em NRAS não foram descritas até hoje. A síndrome autoimune linfoproliferativa (ALPS) é o mais comum defeito genético de apoptose linfocitária, cursando com autoimunidade e acúmulo excessivo de linfócitos, particularmente do tipo T + CD4- CD8-. As mutações causadoras de ALPS descritas até hoje afetam a apoptose mediada por Fas, uma das vias extrínsecas de apoptose. Nós demonstramos aqui que os principais achados clínicos de ALPS, bem como uma predisposição para tumores hematológicos, podem ser causados por uma mutação heterozigota ativadora G13D no oncogene NRAS, sem causar prejuízo na apoptose mediada por Fas. O aumento na quantidade intracelular de NRAS ativo, ligado a GTP, induziu a um aumento da sinalização na via RAF/MEK/ERK, o que suprimiu a expressão da proteína pró-apoptótica BIM, e atenuou a apoptose intrínseca mitocondrial. Desta forma, uma mutação germinativa ativadora em NRAS causou um fenótipo clinico diferente do visto em pacientes com mutações em outros membros da família p21 RAS, cursando com um defeito imunológico seletivo, sem distúrbios generalizados do desenvolvimento / The p21 RAS subfamily of small GTPases, including KRAS, HRAS, and NRAS, regulates cell proliferation, cytoskeletal organization and other signaling networks, and is the most frequent target of activating mutations in cancer. Activating germline mutations of KRAS and HRAS cause severe developmental abnormalities leading to Noonan, cardio-facial-cutaneous and Costello syndrome, but activating germline mutations of NRAS have not been reported. Autoimmune lymphoproliferative syndrome (ALPS) is the most common genetic disease of lymphocyte apoptosis and causes autoimmunity as well as excessive lymphocyte accumulation, particularly of CD4-, CD8- ab T cells. Mutations in ALPS typically affect Fas-mediated apoptosis, but certain ALPS individuals have no such mutations. We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair Fas-mediated apoptosis. The increase in active, GTP-bound NRAS augmented RAF/MEK/ERK signaling which markedly decreased the pro-apoptotic protein BIM and attenuated intrinsic, nonreceptor-mediated mitochondrial apoptosis. Thus, germline activating mutations in NRAS differ from other p21 Ras oncoproteins by causing selective immune abnormalities without general developmental defects

L'échinococcose alvéolaire (EA) est une maladie parasitaire en relation non seulement avec la destruction hépatique quiaccompagne le développement du stade larvaire (métacestode) d'Echinococcus multilocularis, mais aussi avecl'importante réponse immunitaire granulomateuse qui l'entoure. La plupart des travaux antérieurs visant à caractériser le;relations hôte-parasite ont porté sur les cellules de l'immunité dans des sites éloignés de l'habituelle localisationparasitaire, dans le foie. Ce travail de thèse rapporte les mécanismes impliqués dans les modifications de l'homéostasiehépatique aux différents stades de l'infection, mais aussi l'analyse détaillée des profils de cytokines et chimiokinesprésents dans l'infiltrât cellulaire périparasitaire hépatique, de la présence du transforming growth factor-beta et desautres acteurs de sa voie d'activation, et de l'implication possible du Fibrinogen-like protein-2 (FGL2), une moléculeeffectrice des lymphocytes T-régulateurs récemment identifiée. Les résultats indiquent que la réaction inflammatoire quientoure le métacestode dans le foie contribue significativement à la sécrétion de cytokines et de chimiokines et auxmécanismes fonctionnels immunitaires de l'interaction hôte-parasite ; ils révèlent aussi pour la première foisl'intervention cruciale de FGL2 dans la tolérance vis-à-vis d'£. multilocularis. Ces résultats contribuent à identifier denouvelles cibles pour une thérapeutique immunologique qui permettrait de pallier les conséquences pathologiques del'infection par E. multilocularis et de complémenter l'action seulement parasitostatique des benzimidazoles, seuls agentsthérapeutiques connus actuellement. / Alveolar echinococcosis (AE) is a parasitic disease predominantly caused not only by thé direct hepatic damage whichfollows thé continuous tumor-like prolifération of thé larval stage (métacestode) of Echinococcus multilocularis, but alsoindirectly by thé intense local granulomatous immune response which surrounds thé parasitic tissue. Most of previousstudies which aimed at characterizing thé host-parasite relationship hâve been performed on cells of thé immune responsiin peripheral sites, far from thé usual location of E. multilocularis larvae, i.e. thé liver. This PhD thesis reports on thémechanisms involved in thé changes in hepatic homeostatis at thé various stages of infection, and also on a detailedanalysis of thé cytokine and chemokine profiles in thé hepatic periparasitic cell infiltrate, of thé présence of transforminggrowth factor-beta and other actors of its metabolic pathway, and of thé possible involvement of Fibrinogen-like protein-:(FGL2), a recently identified effector molécule of T-regulatory lymphocytes. Results indicate that thé inflammatoryreaction which surrounds thé métacestode in thé liver significantly contributes to cytokine and chemokine sécrétion and tthé functional immune mechanisms of thé host-parasite interactions; they also reveal for thé first time thé crucialintervention of FGL2 in thé tolérance towards E. multilocularis. Thèse results contribute to identify new targets fortherapeutic immune modulation in order to alleviate thé pathological conséquences of E. multilocularis and tocomplément thé parasitostatic-only action of benzimidazoles, thé currently available chemotherapy of thé disease

The genus Mycobacterium comprises some of the most devastating pathogens that infect humans. Mycobacterium tuberculosis causes tuberculosis in humans leading to high morbidity and mortality. The disease is especially prevalent in the under-developed and developing countries of the tropics. Diseases like AIDS and cancer compromise the immune system of an individual leaving him/her susceptible to secondary infections, particularly of tuberculosis. Thus, tuberculosis is making reappearance even in the well-developed countries of the west. The emergence of multi drug resistant strains of tuberculosis makes this deadly disease difficult to cure. A vaccine against tuberculosis is therefore the need of the hour. Mycobacterium smegmatis is a non-pathogenic member of the same family. It has a relatively fast multiplication time when compared to M. tuberculosis and shares the same unique features of the family that make pathogenic members extremely resistant to chemicals and drugs. Proteins of M. smegmatis and M. tuberculosis share high sequence identities, making M. smegmatis the microorganism of choice to study its more deadly counterpart from the same family. A striking feature of all mycobacterial genomes is the abundance of genes coding for enzymes involved in fatty acid and lipid metabolism; more than 250 in Mycobacterium tuberculosis compared to only 50 in Escherichia coli. The mycobacterial genome codes for over a hundred enzymes involved in fatty acid degradation. Apart from providing energy, lipids and fatty acids also form an integral part of the cell wall and cell membrane of Mycobacteria. The abundance and importance of lipid metabolizing enzymes in Mycobacteria make them attractive targets for drug discovery. It is therefore of interest to biochemically and structurally characterize these enzymes. Thiolases are a group of enzymes that are involved in lipid metabolism. In the last step of the β-oxidation pathway, degradative thiolases catalyze the shortening of fatty acid chains by degrading 3-keto acyl CoA to acetyl CoA and a shortened acyl CoA molecule. Thiolases are a subfamily of the thiolase superfamily. This superfamily also includes the Ketoacyl-(Acyl-carrier-protein)-Synthase (KAS) enzymes, polyketide synthases and chalcone synthases. Most members of this superfamily are dimers and while only a few have been found to be tetramers. The tetramers are loosely held dimers of tight dimers. Examination of the Mycobacterium smegmatis genome revealed the presence of several putative thiolase genes. These genes have been annotated as thiolases on the basis of sequence analysis. However, none of them has been biochemically or structurally characterized. The sequence identity between some of these proteins and the other well-characterized thiolases is rather low. The work described in this thesis attempts to characterize two such enzymes from M. smegmatis structurally and functionally. Chapter 1 begins with a brief introduction to the genus Mycobacteria and the role of fatty acid metabolism in mycobacterial virulence. This is followed by a review of the current literature on the enzymes of the thiolase superfamily and their role in fatty acid metabolism. The chapter concludes with a brief summary on the aims and objectives of the work. Chapter 2 describes all the common experimental procedures and computational methods used during the course of these investigations, as most of them are applicable to all the structure determinations and analyses presented in later chapters. The experimental procedures described include overexpression, purification, site directed mutagenesis, isolation of plasmids, crystallization of proteins and X-ray diffraction data collection. Computational methods include structure determination protocols along with details of various programs used during data processing, structure determination, refinement, model building, structure validation and analysis. Chapter 3 describes the cloning, expression, purification, crystallization and structure determination of a thiolase-like protein (TLP1) from M. smegmatis. All enzymes of the thiolase superfamily that have been structurally characterized so far share four features: 1) conservation of the core α/β/α/β/α-layered structure of the thiolase domain, 2) conservation of the extensive dimerization interface, 3) the location of the active site pocket and conservation of key active site residues and 4) the use of a nucleophilic cysteine residue in catalysis. The crystal structure of MsTLP1 revealed some interesting differences when compared to classical thiolases. Of the four characteristic features of thiolases, MsTLP1 has the conserved thiolase fold. The location of its putative active site is similar to that in classical thiolases. However, the dimerization is not a conserved feature in MsTLP1, which appears to be a monomer in solution as well as in the crystal structure. The ligand binding groove of MsTLP1, identified by structural superposition with Z. ramigera thiolase, is larger than that of Z. ramigera. The absence of the catalytic cysteine suggested that though the protein has the strictly conserved thiolase fold, it might perform an entirely different function. A unique extra C-terminal domain of unknown function present only in MsTLP1 has been described towards the end of the chapter. A thorough sequence and structural analysis suggested that MsTLP1 might belong to a new subfamily in the thiolase superfamily. Chapter 4 describes the attempts made towards the biochemical characterization of MsTLP1. Thiolase assays carried out for the synthetic and degradative reactions revealed that the enzyme is inactive in both the directions. However, surface plasmon resonance binding studies revealed that the protein could bind to Coenzyme A, a feature it shares with other enzymes of the thiolase superfamily. Thorough bioinformatics analyses of the structure to determine the residues involved in CoA binding have also been described. The chapter ends with a discussion on the probable function of TLPs in Mycobacteria. Chapter 5 describes the cloning, expression, purification and X-ray structural studies on MsT1-L thiolase. This is the first structural report of a probable T1-thiolase. The protein crystallized in three different space groups, in all of which the enzyme was found to be in a tetrameric form. Analysis of the tetramer structures from the three different crystal forms revealed that MsT1-L exhibits some rotational flexibility about the central tetramerization loop. A qualitative and quantitative analysis of this movement has been described. Structural comparisons revealed that the overall structure of MsT1-L is very similar to that of the well-characterized biosynthetic thiolase form Z. ramigera. However, a detailed analysis of the ordered waters near the active site cavity revealed interesting differences between the two. The probable functional relevance of this observation has been discussed. The crystal structure of MsT1-L complexed with CoA has also been described in detail. Structural comparisons with classical thiolases also revealed significant differences in the organization of the loop domain that harbors most of the residues required for catalysis. These differences cause the active site cavity of MsT1-L to be larger than that of biosynthetic thiolase suggesting that MsT1-L thiolase could probably bind larger substrates. This cavity is large enough to accommodate a medium chain length fatty acyl CoA as substrate. Co-crystallization experiments with hexanoyl CoA revealed a novel binding site for the fatty acyl chain in MsT1-L and this has been described in detail. Contributions made towards the cloning and expression of other thiolases from S. typhimurium and P. falciparum have been described in Chapters 6 and 7. The thesis concludes with a brief discussion on the future prospects of the investigations presented here.

No description available.

No description available.

INTRODUÇÃO: As doenças retinianas associadas à neovascularização, tais como a degeneração macular relacionada à idade e as retinopatias diabética e da prematuridade são as principais e mais importantes causas da cegueira em todo o mundo. Nos últimos anos, injeções intravítreas de fármacos com ação antiangiogênica, como o bevacizumabe (BVZ), têm sido de grande valia tanto em pacientes na fase adulta quanto nos recém-natos. Todavia, estudos experimentais in vitro e in vivo sugerem que essas drogas promovam efeitos adversos sobre alguns processos celulares, interferindo diretamente em mecanismos fisiológicos que mantém a homeostase do tecido retiniano, incluindo os mecanismos de proliferação, diferenciação e morte celular. OBJETIVO: investigar o efeito do BVZ nos processos de transcrição e tradução de marcadores da gliose: GFAP e vimentina, de morte celular, caspase-3 e beclina-1, e dos proteoglicanos relacionados à manutenção e desenvolvimento de tecido retiniano: neurocam, fosfacam e sindecam-3. MÉTODOS: Dois modelos experimentais foram usados nesse estudo: 1) linhagem celular de Müller de Glia humana adulta (MIO-M1), cultivada em meio de cultura D-MEM na presença e ausência de BVZ por 12 e 24 horas nas concentrações de 0,25 mg/mL e 0,50 mg/mL e 2) explantes de retinas de ratos 2 dias pós-nascidos submetidos à 0,50 mg/mL da droga por 48 horas. Durante este período foram mantidos a 5% de dióxido de carbono à temperatura de 37°C. A análise de proteínas foi realizada por imunocitohistoquímica e Western Blotting e a expressão de RNAm, pela reação em cadeia da polimerase em tempo real (PCR Real Time). Foi utilizado o Teste de ANOVA - fator único para a comparação entre os grupos controle e tratados com BVZ de um mesmo período (12h ou 24h) e o teste t de Student para a comparação entre as mesmas concentrações de 12h e 24h, e para a comparação entre os grupos controle e tratado com BVZ dos explantes (p < 0,05). RESULTADOS: Nas células MIO-M1, o BVZ, aumentou a expressão gênica e diminui a tradução de VEGF na concentração de 0,50 mg/mL em 24h comparado a 12h. Para o GFAP, houve um aumento da transcrição em 0,50 mg/mL em 24h comparado a 12h e aos outros grupos em 24h. Entretanto, houve diminuição da tradução para estes mesmos períodos e condições. Para a vimentina, houve aumento na transcrição em 0,50 mg/mL após 24h. Os achados de beclina-1 revelaram uma diminuição da transcrição e tradução em 0,25 mg/mL em 24h comparado a 12h. A transcrição entre os grupos do mesmo período aumentou nos grupos tratados com BVZ tanto em 12h quanto em 24h. A tradução da beclina-1 diminuiu em 0,25 mg/mL, mas aumentou em 0,50 mg/mL em 24h em relação à 12h. A comparação entre os grupos de 24h revelou aumento da tradução em 0,50 mg/mL. Para a caspase-3, houve diminuição da transcrição em 0,25 mg/mL e 0,50 mg/mL em 24h em relação a 12h e entre nos grupos tratados com BVZ em 24h. A tradução revelou um aumento em 0,50 mg/mL em 24h em relação a 12h. No fosfacam, houve diminuição da transcrição em 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles para 12h e 24h. A transcrição de neurocam diminuiu em 0,25 mg/mL e 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles em 12h e 24h. A tradução aumentou em 0,50 mg/mL em 24h em relação a 12h, mas diminuiu entre os grupos em 24h. Nos explantes, a transcrição e tradução de VEGF diminuiram no grupo tratado com BVZ após 48h. CONCLUSÃO: Nossos resultados relacionados às células MIO-M1 e ao explante de ratos, in vitro, nos permitem aventar o possível comprometimento ocasionado pela depleção do VEGF pelo BVZ na homeostase do tecido retiniano, in vivo, interferindo nas moléculas envolvidas na morte e diferenciação celular e na neuroproteção em indivíduos em fase adulta e recém-nato / Backgraound: Vasoproliferative retinal disorders such as age-related macular, degeneration, diabetic retinopathy and retinopathy of prematurity are major causes of blindness in the world. In recent years, intravitreal injections of drugs with antiangiogenic action, as bevacizumab, have been very useful for both patients in adulthood and in newborns. However, experimental studies, in vivo and in vitro, suggest that antiangiogenic drugs may promote side effects in cellular proceedings, interfering directly in physiological mechanisms of cellular proliferation, differentiation and death. POURPOSE: Investigate the bevacizumab effects in transcription and translation processes of gliosis, GFAP and vimentin, cellular death markers, caspase-3 and beclin-1, and proteoglycans involved in retinal tissue maintenance and development, neurocan, phosphacan and syndecan-3. METHODS: Two experimental models were used on this research: cellular lineage of adult and human Müller glial cell(MIO-M1) were cultivated on D-MEM medium with 0,25 and 0,50 mg/mL bevacizumab for 12 and 24 hours, and two days old rat retinal explants submitted to 0,50 mg/mL for 48 hours. During this period were stored in laboratory ovens at 5% carbon dioxide pressure and 37 °C average temperature. Molecular techniques were used to evaluate gene expression and protein content. Protein assessments were performed by immunocytochemistry and western blotting analysis, while Real Time PCR was used to measure mRNA content. ANOVA tests one factor were applied to compare the control and BVZ groups of the same period (12h or 24h) and t test from Student to compare the same conditions of 12h and 24h, and to compare the control and BVZ retinal explants groups (p<0.05). RESULTS: At MIO-M1 cells, BVZ increased the gene expression and reduced the translation of VEGF at concentration of 0.50 mg / mL in 24 hours compared to 12 hours. For GFAP, there was an increase of transcription at 0.50 mg / mL in 24 hours compared to 12 hours and to the other groups at 24 hours. However, there was a decrease in translation for these same periods and conditions. For vimentin, there was an increase in transcription at 0.50 mg / mL after 24 hours. The beclin-1 findings revealed a decrease of transcription and translation at 0.25 mg / ml compared at 24 h compared to 12h. Transcription among groups increased in BVZ treated groups at 12h and 24h. The translation of beclin-1 decreased at 0.25 mg / ml, but increased at 0.50 mg / mL at 24 hours compared to 12 hours. The comparison between the groups at 24h revealed an increased in translation at 0.50 mg / mL. For caspase-3, there was a decrease in transcription at 0.25 mg / ml and 0.50 mg / ml at 24 compared to 12 hours and among BVZ treated groups at 24h. Translation revealed an increase at 0.50 mg / mL at 24 hours compared to 12 hours. For fosfacam, there was a decreased in transcription at 0.50 mg / mL in 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. The transcription of neurocam decreased at 0.25 mg / ml and 0.50 mg / ml at 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. Translation increased at 0.50 mg / mL at 24 compared to 12 hours, but decreased among the groups at 24 hours. For explants, transcription and translation of VEGF decreased in the BVZ group treated after 48h. CONCLUSION: Our results related to the MIO-M1 cells and explants of rats,in vitro, allow us to suggest the possible impairment caused by depletion of VEGF by BVZ in the homeostasis of retinal tissue, in vivo, interfering in the molecules involved in cell death and cell differentiation and neuroprotection in individuals in adulthood and newborns

INTRODUÇÃO: As doenças retinianas associadas à neovascularização, tais como a degeneração macular relacionada à idade e as retinopatias diabética e da prematuridade são as principais e mais importantes causas da cegueira em todo o mundo. Nos últimos anos, injeções intravítreas de fármacos com ação antiangiogênica, como o bevacizumabe (BVZ), têm sido de grande valia tanto em pacientes na fase adulta quanto nos recém-natos. Todavia, estudos experimentais in vitro e in vivo sugerem que essas drogas promovam efeitos adversos sobre alguns processos celulares, interferindo diretamente em mecanismos fisiológicos que mantém a homeostase do tecido retiniano, incluindo os mecanismos de proliferação, diferenciação e morte celular. OBJETIVO: investigar o efeito do BVZ nos processos de transcrição e tradução de marcadores da gliose: GFAP e vimentina, de morte celular, caspase-3 e beclina-1, e dos proteoglicanos relacionados à manutenção e desenvolvimento de tecido retiniano: neurocam, fosfacam e sindecam-3. MÉTODOS: Dois modelos experimentais foram usados nesse estudo: 1) linhagem celular de Müller de Glia humana adulta (MIO-M1), cultivada em meio de cultura D-MEM na presença e ausência de BVZ por 12 e 24 horas nas concentrações de 0,25 mg/mL e 0,50 mg/mL e 2) explantes de retinas de ratos 2 dias pós-nascidos submetidos à 0,50 mg/mL da droga por 48 horas. Durante este período foram mantidos a 5% de dióxido de carbono à temperatura de 37°C. A análise de proteínas foi realizada por imunocitohistoquímica e Western Blotting e a expressão de RNAm, pela reação em cadeia da polimerase em tempo real (PCR Real Time). Foi utilizado o Teste de ANOVA - fator único para a comparação entre os grupos controle e tratados com BVZ de um mesmo período (12h ou 24h) e o teste t de Student para a comparação entre as mesmas concentrações de 12h e 24h, e para a comparação entre os grupos controle e tratado com BVZ dos explantes (p < 0,05). RESULTADOS: Nas células MIO-M1, o BVZ, aumentou a expressão gênica e diminui a tradução de VEGF na concentração de 0,50 mg/mL em 24h comparado a 12h. Para o GFAP, houve um aumento da transcrição em 0,50 mg/mL em 24h comparado a 12h e aos outros grupos em 24h. Entretanto, houve diminuição da tradução para estes mesmos períodos e condições. Para a vimentina, houve aumento na transcrição em 0,50 mg/mL após 24h. Os achados de beclina-1 revelaram uma diminuição da transcrição e tradução em 0,25 mg/mL em 24h comparado a 12h. A transcrição entre os grupos do mesmo período aumentou nos grupos tratados com BVZ tanto em 12h quanto em 24h. A tradução da beclina-1 diminuiu em 0,25 mg/mL, mas aumentou em 0,50 mg/mL em 24h em relação à 12h. A comparação entre os grupos de 24h revelou aumento da tradução em 0,50 mg/mL. Para a caspase-3, houve diminuição da transcrição em 0,25 mg/mL e 0,50 mg/mL em 24h em relação a 12h e entre nos grupos tratados com BVZ em 24h. A tradução revelou um aumento em 0,50 mg/mL em 24h em relação a 12h. No fosfacam, houve diminuição da transcrição em 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles para 12h e 24h. A transcrição de neurocam diminuiu em 0,25 mg/mL e 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles em 12h e 24h. A tradução aumentou em 0,50 mg/mL em 24h em relação a 12h, mas diminuiu entre os grupos em 24h. Nos explantes, a transcrição e tradução de VEGF diminuiram no grupo tratado com BVZ após 48h. CONCLUSÃO: Nossos resultados relacionados às células MIO-M1 e ao explante de ratos, in vitro, nos permitem aventar o possível comprometimento ocasionado pela depleção do VEGF pelo BVZ na homeostase do tecido retiniano, in vivo, interferindo nas moléculas envolvidas na morte e diferenciação celular e na neuroproteção em indivíduos em fase adulta e recém-nato / Backgraound: Vasoproliferative retinal disorders such as age-related macular, degeneration, diabetic retinopathy and retinopathy of prematurity are major causes of blindness in the world. In recent years, intravitreal injections of drugs with antiangiogenic action, as bevacizumab, have been very useful for both patients in adulthood and in newborns. However, experimental studies, in vivo and in vitro, suggest that antiangiogenic drugs may promote side effects in cellular proceedings, interfering directly in physiological mechanisms of cellular proliferation, differentiation and death. POURPOSE: Investigate the bevacizumab effects in transcription and translation processes of gliosis, GFAP and vimentin, cellular death markers, caspase-3 and beclin-1, and proteoglycans involved in retinal tissue maintenance and development, neurocan, phosphacan and syndecan-3. METHODS: Two experimental models were used on this research: cellular lineage of adult and human Müller glial cell(MIO-M1) were cultivated on D-MEM medium with 0,25 and 0,50 mg/mL bevacizumab for 12 and 24 hours, and two days old rat retinal explants submitted to 0,50 mg/mL for 48 hours. During this period were stored in laboratory ovens at 5% carbon dioxide pressure and 37 °C average temperature. Molecular techniques were used to evaluate gene expression and protein content. Protein assessments were performed by immunocytochemistry and western blotting analysis, while Real Time PCR was used to measure mRNA content. ANOVA tests one factor were applied to compare the control and BVZ groups of the same period (12h or 24h) and t test from Student to compare the same conditions of 12h and 24h, and to compare the control and BVZ retinal explants groups (p<0.05). RESULTS: At MIO-M1 cells, BVZ increased the gene expression and reduced the translation of VEGF at concentration of 0.50 mg / mL in 24 hours compared to 12 hours. For GFAP, there was an increase of transcription at 0.50 mg / mL in 24 hours compared to 12 hours and to the other groups at 24 hours. However, there was a decrease in translation for these same periods and conditions. For vimentin, there was an increase in transcription at 0.50 mg / mL after 24 hours. The beclin-1 findings revealed a decrease of transcription and translation at 0.25 mg / ml compared at 24 h compared to 12h. Transcription among groups increased in BVZ treated groups at 12h and 24h. The translation of beclin-1 decreased at 0.25 mg / ml, but increased at 0.50 mg / mL at 24 hours compared to 12 hours. The comparison between the groups at 24h revealed an increased in translation at 0.50 mg / mL. For caspase-3, there was a decrease in transcription at 0.25 mg / ml and 0.50 mg / ml at 24 compared to 12 hours and among BVZ treated groups at 24h. Translation revealed an increase at 0.50 mg / mL at 24 hours compared to 12 hours. For fosfacam, there was a decreased in transcription at 0.50 mg / mL in 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. The transcription of neurocam decreased at 0.25 mg / ml and 0.50 mg / ml at 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. Translation increased at 0.50 mg / mL at 24 compared to 12 hours, but decreased among the groups at 24 hours. For explants, transcription and translation of VEGF decreased in the BVZ group treated after 48h. CONCLUSION: Our results related to the MIO-M1 cells and explants of rats,in vitro, allow us to suggest the possible impairment caused by depletion of VEGF by BVZ in the homeostasis of retinal tissue, in vivo, interfering in the molecules involved in cell death and cell differentiation and neuroprotection in individuals in adulthood and newborns